See more : LuxNet Corporation (4979.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Cardax, Inc. (CDXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardax, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ZIOPHARM Oncology, Inc. (ZIOP) Income Statement Analysis – Financial Results
- ID Logistics Group SA (0QAG.L) Income Statement Analysis – Financial Results
- Shionogi & Co., Ltd. (SGIOF) Income Statement Analysis – Financial Results
- Bangsaphan Barmill Public Company Limited (BSBM.BK) Income Statement Analysis – Financial Results
- Volkswagen AG (VLKPF) Income Statement Analysis – Financial Results
Cardax, Inc. (CDXI)
About Cardax, Inc.
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 538.95K | 710.95K | 1.51M | 610.32K | 35.26K | 0.00 | 0.00 | 75.35K | 72.69K |
| Cost of Revenue | 0.00 | 0.00 | 196.13K | 345.39K | 699.85K | 274.71K | 14.58K | 4.40M | 0.00 | 65.17K | 61.76K |
| Gross Profit | 0.00 | 0.00 | 342.82K | 365.56K | 811.02K | 335.62K | 20.68K | -4.40M | 0.00 | 10.19K | 10.93K |
| Gross Profit Ratio | 0.00% | 0.00% | 63.61% | 51.42% | 53.68% | 54.99% | 58.65% | 0.00% | 0.00% | 13.52% | 15.03% |
| Research & Development | 0.00 | 0.00 | 136.78K | 315.99K | 269.08K | 460.99K | 347.89K | 491.83K | 1.16M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 3.23M | 4.09M | 4.53M | 1.31M | 1.36M | 2.93M | 15.68M | 45.34K | 20.66K |
| Selling & Marketing | 0.00 | 0.00 | 27.37 | 161.47 | 0.00 | 535.24K | 117.18K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 3.23M | 4.09M | 4.53M | 1.85M | 1.47M | 2.93M | 15.68M | 45.34K | 20.66K |
| Other Expenses | 0.00 | 0.00 | 34.52K | 39.57K | 30.57K | 29.42K | 29.10K | 23.76K | 38.97K | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 3.41M | 4.44M | 4.83M | 2.34M | 1.85M | 3.44M | 16.88M | 45.34K | 20.66K |
| Cost & Expenses | 0.00 | 0.00 | 3.60M | 4.79M | 5.53M | 2.61M | 1.87M | 3.44M | 16.88M | 110.51K | 82.43K |
| Interest Income | 0.00 | 0.00 | 2.38K | 623.42 | 1.94K | 3.32K | 2.36K | 2.36K | 3.69K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 2.38M | 623.42K | 4.23K | 3.54K | 2.93K | 2.33K | 118.78K | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 34.52K | 39.57K | 30.57K | 29.42K | 29.10K | 23.76K | 38.97K | 24.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | -2.64M | -4.04M | -3.99M | -1.97M | -1.75M | -4.23M | -16.84M | -65.13K | -35.16K |
| EBITDA Ratio | 0.00% | 0.00% | -585.57% | -567.91% | -264.05% | -319.88% | -4,968.17% | 0.00% | 0.00% | -86.43% | -13.39% |
| Operating Income | 0.00 | 0.00 | -3.06M | -4.08M | -4.02M | -2.00M | -1.83M | -4.40M | -16.88M | -65.16K | -9.74K |
| Operating Income Ratio | 0.00% | 0.00% | -568.26% | -573.47% | -266.24% | -328.07% | -5,190.95% | 0.00% | 0.00% | -86.47% | -13.39% |
| Total Other Income/Expenses | 0.00 | 0.00 | -1.99M | -1.02M | -1.73K | 17.04K | 46.52K | 143.23K | -112.66K | -769.42K | -63.36K |
| Income Before Tax | 0.00 | 0.00 | -5.06M | -5.09M | -4.02M | -1.99M | -1.78M | -4.26M | -16.99M | -65.16K | -9.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | -938.04% | -716.37% | -266.35% | -325.28% | -5,059.01% | 0.00% | 0.00% | -86.47% | -13.39% |
| Income Tax Expense | 0.00 | 0.00 | 2.26M | 623.42K | 4.78K | 20.79K | 50.01K | -813.04K | 121.21K | -30.00K | 0.00 |
| Net Income | 0.00 | 0.00 | -7.31M | -5.72M | -4.02M | -1.99M | -1.78M | -4.26M | -16.99M | -65.16K | -9.74K |
| Net Income Ratio | 0.00% | 0.00% | -1,356.78% | -804.06% | -266.35% | -325.28% | -5,059.01% | 0.00% | 0.00% | -86.47% | -13.39% |
| EPS | 0.00 | 0.00 | -9.82 | -8.40 | -6.32 | -3.97 | -4.68 | -12.73 | -56.44 | -0.28 | -0.04 |
| EPS Diluted | 0.00 | 0.00 | -9.82 | -8.40 | -6.32 | -3.97 | -4.68 | -12.73 | -56.44 | -0.28 | -0.04 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 744.56K | 680.15K | 636.52K | 499.76K | 381.14K | 334.37K | 301.13K | 231.66K | 221.43K |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 744.56K | 680.15K | 636.52K | 499.76K | 381.14K | 334.37K | 301.13K | 231.66K | 221.43K |
Source: https://incomestatements.info
Category: Stock Reports